A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
Public ClinicalTrials.gov record NCT01085097. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination With Standard of Care (Mycophenolate Mofetil and Steroids)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules in active lupus nephritis participants. This study will assess Laquinimod doses of 0.5 milligrams (mg)/day and 1 mg/day in combination with standard of care treatment (mycophenolate mofetil \[MMF\] and corticosteroids). Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for Multiple Sclerosis.
Study identification
- NCT ID
- NCT01085097
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Interventions
- Laquinimod Drug
- Mycophenolate Mofetil Drug
- Prednisolone/Prednisone Drug
- Placebo Drug
- Methylprednisolone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2010
- Primary completion
- Oct 23, 2012
- Completion
- Oct 23, 2012
- Last update posted
- Mar 8, 2022
2010 – 2012
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 1032 | Phoenix | Arizona | 85012 | — |
| Teva Investigational Site 1024 | La Jolla | California | 92037-0943 | — |
| Teva Investigational Site 1028 | Los Angeles | California | 90048 | — |
| Teva Investigational Site 1025 | San Leandro | California | 94578 | — |
| Teva Investigational Site 1031 | Baltimore | Maryland | 21205 | — |
| Teva Investigational Site 1021 | Rochester | Minnesota | 55905 | — |
| Teva Investigational Site 1022 | Lake Success | New York | 11042 | — |
| Teva Investigational Site 1018 | Manhasset | New York | 11030 | — |
| Teva Investigational Site 1019 | New York | New York | 10016 | — |
| Teva Investigational Site 1017 | New York | New York | 10032 | — |
| Teva Investigational Site 1020 | Charlotte | North Carolina | 28210 | — |
| Teva Investigational Site 1016 | Columbus | Ohio | 43210 | — |
| Teva Investigational Site 1030 | Charleston | South Carolina | 29425 | — |
| Teva Investigational Site 1026 | Chattanooga | Tennessee | 37408 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01085097, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2022 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01085097 live on ClinicalTrials.gov.